JAB1/CSN5: a new player in cell cycle control and cancer

被引:0
|
作者
Terry J Shackleford
Francois X Claret
机构
[1] The University of Texas MD Anderson Cancer Center,Department of Systems Biology
来源
Cell Division | / 5卷
关键词
Small Complex; Psoriasin; Tumorigenic Process; COP9 Signalosome; Isopeptidase Activity;
D O I
暂无
中图分类号
学科分类号
摘要
c-Jun activation domain-binding protein-1 (Jab1) acts as a modulator of intracellular signaling and affects cellular proliferation and apoptosis, through its existence as a monomer or as the fifth component of the constitutive photomorphogenic-9 signalosome (CSN5). Jab1/ CSN5 is involved in transcription factor specificity, deneddylation of NEDD8, and nuclear-to-cytoplasmic shuttling of key molecules. Jab1/CSN5 activities positively and negatively affect a number of pathways, including integrin signaling, cell cycle control, and apoptosis. Also, more recent studies have demonstrated the intriguing roles of Jab1/CSN5 in regulating genomic instability and DNA repair. The effects of Jab1/CSN5's multiple protein interactions are generally oncogenic in nature, and overexpression of Jab1/CSN5 in cancer provides evidence that it is involved in the tumorigenic process. In this review, we highlight our current knowledge of Jab1/CSN5 function and the recent discoveries in dissecting the Jab1 signaling pathway. Further, we also discuss the regulation of Jab1/CSN5 in cancers and its potential as a therapeutic target.
引用
收藏
相关论文
共 50 条
  • [1] JAB1/CSN5: a new player in cell cycle control and cancer
    Shackleford, Terry J.
    Claret, Francois X.
    CELL DIVISION, 2010, 5
  • [2] The emerging roles of Jab1/CSN5 in cancer
    Lin Wang
    Jun-Nian Zheng
    Dong-Sheng Pei
    Medical Oncology, 2016, 33
  • [3] The emerging roles of Jab1/CSN5 in cancer
    Wang, Lin
    Zheng, Jun-Nian
    Pei, Dong-Sheng
    MEDICAL ONCOLOGY, 2016, 33 (08)
  • [4] CSN5/Jab1 controls multiple events in the mammalian cell cycle
    Yoshida, Akihiro
    Yoneda-Kato, Noriko
    Panattoni, Martina
    Pardi, Ruggero
    Kato, Jun-ya
    FEBS LETTERS, 2010, 584 (22): : 4545 - 4552
  • [5] Targeting Jab1/CSN5 in nasopharyngeal carcinoma
    Pan, Yunbao
    Claret, Francois X.
    CANCER LETTERS, 2012, 326 (02) : 155 - 160
  • [6] Jab1/Csn5: a new player driving the resistance to HER2-targeted therapies for breast cancer
    Claret, F.
    Vu, T.
    Shackleford, T. J.
    Allensworth, J. L.
    Zhang, Q.
    Esteva, F. J.
    Drakos, E.
    Zhang, R.
    Tian, L.
    Rassidakis, G. Z.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 155 - 155
  • [7] MAbs against mammalian Jab1/CSN5 protein
    Kato, Jun-Ya
    HYBRIDOMA, 2006, 25 (06): : 387 - 387
  • [8] Jab1/Csn5 a new player driving the resistance to Her2-targeted therapies for breast cancer.
    Vu, Thuy T.
    Shackleford, Terry J.
    Zhang, Qingxiu
    Esteva, Francisco J.
    Drakos, Elias
    Tian, Ling
    Kute, Timothy
    Sahin, Aysegul A.
    Rassidakis, George Z.
    Claret, Francois X.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [9] Role of CSN5/JAB1 in Wnt/β-catenin activation in colorectal cancer cells
    Schuetz, Anke K.
    Hennes, Thomas
    Jumpertz, Sandra
    Fuchs, Simone
    Bernhagen, Juergen
    FEBS LETTERS, 2012, 586 (11): : 1645 - 1651
  • [10] Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression
    Pan, Y.
    Wang, S.
    Su, B.
    Zhou, F.
    Zhang, R.
    Xu, T.
    Zhang, R.
    Leventaki, V.
    Drakos, E.
    Liu, W.
    Claret, F. X.
    ONCOGENE, 2017, 36 (08) : 1069 - 1079